FI960045A0 - Solujen valmistus ja stabilointi - Google Patents

Solujen valmistus ja stabilointi

Info

Publication number
FI960045A0
FI960045A0 FI960045A FI960045A FI960045A0 FI 960045 A0 FI960045 A0 FI 960045A0 FI 960045 A FI960045 A FI 960045A FI 960045 A FI960045 A FI 960045A FI 960045 A0 FI960045 A0 FI 960045A0
Authority
FI
Finland
Prior art keywords
blood
leucocytes
composition
stabilizing
novel
Prior art date
Application number
FI960045A
Other languages
English (en)
Swedish (sv)
Other versions
FI960045A (fi
Inventor
Vivian Granger
David Barnett
John Tennison Reilly
Petra Susanne Maria Mayr
Shawn Patrick Fay
Original Assignee
North Gen Hospital Nhs Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939313962A external-priority patent/GB9313962D0/en
Priority claimed from GB9406698A external-priority patent/GB9406698D0/en
Application filed by North Gen Hospital Nhs Trust filed Critical North Gen Hospital Nhs Trust
Publication of FI960045A publication Critical patent/FI960045A/fi
Publication of FI960045A0 publication Critical patent/FI960045A0/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5002—Partitioning blood components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Ecology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FI960045A 1993-07-05 1996-01-05 Solujen valmistus ja stabilointi FI960045A0 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB939313962A GB9313962D0 (en) 1993-07-05 1993-07-05 Preparation and stabilisation of leucocytes
GB939315871A GB9315871D0 (en) 1993-07-05 1993-07-20 Preparation and stabilisation of leucocytes
GB9406698A GB9406698D0 (en) 1994-04-05 1994-04-05 Preparation and stabilisation of cell suspensions
PCT/EP1994/002189 WO1995001796A1 (en) 1993-07-05 1994-07-05 Preparation and stabilisation of cells

Publications (2)

Publication Number Publication Date
FI960045A FI960045A (fi) 1996-01-05
FI960045A0 true FI960045A0 (fi) 1996-01-05

Family

ID=27266764

Family Applications (1)

Application Number Title Priority Date Filing Date
FI960045A FI960045A0 (fi) 1993-07-05 1996-01-05 Solujen valmistus ja stabilointi

Country Status (14)

Country Link
US (2) US6197540B1 (fi)
EP (1) EP0708649B1 (fi)
JP (1) JPH09503051A (fi)
AT (1) ATE241368T1 (fi)
AU (2) AU700699B2 (fi)
BR (1) BR9407003A (fi)
CA (1) CA2166729A1 (fi)
DE (2) DE708649T1 (fi)
ES (1) ES2197168T3 (fi)
FI (1) FI960045A0 (fi)
GB (1) GB2279653B (fi)
NO (1) NO960049L (fi)
NZ (1) NZ271318A (fi)
WO (1) WO1995001796A1 (fi)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197540B1 (en) 1993-07-05 2001-03-06 Northern General Hospital N.H.S. Trust Preparation and stabilization of cells using aged transition metal solutions
WO1995027203A1 (en) * 1994-04-05 1995-10-12 Northern General Hospital N.H.S. Trust Preparation and stabilisation of cell suspensions
GB2313288B (en) 1996-05-24 2000-07-12 North Gen Hospital Nhs Trust Specimen collection fluid
EP1182457A1 (en) * 2000-08-17 2002-02-27 Mallinckrodt Baker B.V. Method and reagent for the analysis of blood samples, in particular for veterinary applications
US6913932B2 (en) * 2002-08-23 2005-07-05 Beckman Coulter, Inc. Formaldehyde-ammonium salt complexes for the stabilization of blood cells
CA2445204C (en) * 2002-10-16 2014-08-12 Streck Laboratories, Inc. Method and device for collecting and preserving cells for analysis
US7267980B1 (en) 2003-04-04 2007-09-11 Research & Diagnostic Systems, Inc. Stabilizing solution for cells and tissues
US20050085028A1 (en) * 2003-10-21 2005-04-21 International Business Machines Corporation Method and structure to suppress external latch-up
CN100376669C (zh) * 2005-02-25 2008-03-26 深圳迈瑞生物医疗电子股份有限公司 生物红细胞体积长期稳定的处理方法
US20070015134A1 (en) * 2005-07-15 2007-01-18 Beckman Coulter, Inc. Quantitative stabilized cell reference control products and methods
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US9267956B2 (en) * 2008-07-11 2016-02-23 Secretary Of State For Health Stimulated cell standards
WO2010078194A1 (en) 2008-12-30 2010-07-08 Streck, Inc. Method for screening blood using a preservative that may be in a substantially solid state form
US11634747B2 (en) * 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
DE202010018569U1 (de) 2009-02-18 2017-09-26 Streck Inc. Konservierung zellfreier Nukleinsäuren
ES2571104T3 (es) * 2009-11-09 2016-05-24 Streck Inc Estabilización del ARN y extracción del ARN presente en células intactas dentro de una muestra de sangre
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
EP2854058A3 (en) 2010-05-18 2015-10-28 Natera, Inc. Methods for non-invasive pre-natal ploidy calling
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
AU2011358564B9 (en) 2011-02-09 2017-07-13 Natera, Inc Methods for non-invasive prenatal ploidy calling
US9956281B2 (en) 2011-05-04 2018-05-01 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
EP3024323B1 (en) 2013-07-24 2022-10-19 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
EP3561075A1 (en) 2014-04-21 2019-10-30 Natera, Inc. Detecting mutations in tumour biopsies and cell-free samples
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
WO2018022991A1 (en) 2016-07-29 2018-02-01 Streck, Inc. Suspension composition for hematology analysis control
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
CA3050906A1 (en) 2017-01-22 2018-07-26 Chryos, Llc Composition and method of use of the same for preserving cells for analysis
WO2019210306A1 (en) * 2018-04-27 2019-10-31 Momenta Pharmaceuticals , Inc. Blood preparation
US11525159B2 (en) 2018-07-03 2022-12-13 Natera, Inc. Methods for detection of donor-derived cell-free DNA
CN113325171B (zh) * 2021-08-02 2021-12-21 天津康博尔生物基因技术有限公司 检测人体红细胞叶酸含量的试剂盒、检测方法及用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1068862B (de) 1957-05-03 1959-11-12 Penicillin-Gesellschaft Dauelsberg a Co., Göttingen Verfahren zur Verlängerung der Haltbarkeit von Blutkonserven
DE1147004B (de) * 1959-10-16 1963-04-11 Dr Med Herbert Fischer Verfahren zur Konservierung von lebenden menschlichen oder tierischen Zellpraeparaten, insbesondere von Blut und Blutbestandteilen
CA933092A (en) * 1969-04-10 1973-09-04 V. Collins Zeola Method of prolonging the viability of lymphocytes
FR2202688B1 (fi) 1972-10-17 1977-04-15 Cepbepe
US4045488A (en) 1974-11-06 1977-08-30 Pfizer Inc. Aminophenyltetralin compounds
IT1065125B (it) 1975-08-20 1985-02-25 Boehringer Mannheim Gmbh Processo per mantenere costante l attivita di fosfatasi alcalina e siero di controllo contenente tale fosfatasi
DE2551208C3 (de) * 1975-11-14 1981-05-27 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung einer stabilen Erythrozyten-Präparation
US4040785A (en) 1976-10-18 1977-08-09 Technicon Instruments Corporation Lysable blood preservative composition
US4152208A (en) 1977-03-29 1979-05-01 Hoffmann-La Roche Inc. Stabilized leucocytes
DE2828820A1 (de) * 1977-08-01 1979-02-08 Warner Lambert Co Verfahren zur herstellung einer stabilen blutplaettchensuspension und nach dem verfahren erhaltene stabile blutplaettchensuspension
US4302355A (en) * 1977-08-01 1981-11-24 Warner-Lambert Company Platelet reference control
US4324687A (en) 1979-02-15 1982-04-13 Louderback Allan Lee Blood biochemistry control standard
DE2949824A1 (de) * 1979-12-12 1981-07-02 Marianne Dr. 5000 Köln Sehrbundt Verfahren zur stabilisierung von lymphozyten/thrombozytennmischsuspensionen
US4346018A (en) * 1980-06-16 1982-08-24 Coulter Electronics, Inc. Multi-purpose blood diluent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes
US4405719A (en) 1981-05-29 1983-09-20 Coulter Electronics, Inc. Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; diluents therefor; and combination stabilization procedures
US4704352A (en) * 1985-06-25 1987-11-03 Baxter Travenol Laboratories, Inc. L-ascorbate-2-phosphate salts in blood cell storage
EP0231300B1 (de) 1985-08-08 1989-05-24 LISS, Eberhard Verfahren zur Hemmung der Reduktion des Glucose-Gehalts im Blut
US4675185A (en) * 1985-12-06 1987-06-23 Baxter Travenol Laboratories, Inc. Solution for stabilizing red blood cells during storage
US4729959A (en) 1986-02-24 1988-03-08 Streck Laboratories, Inc. Glucose reference control for glucose test strips
US4806343A (en) 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
IT1188132B (it) * 1986-05-07 1987-12-30 Fameccanica Spa Procedimento e dispositivo per la produzione di film perforati particolarmente film perforati di materiale plastico per articoli igienico sanitari
US5250438A (en) 1990-05-09 1993-10-05 Streck Laboratories, Inc. Method for differential determination of white blood cells using diazolidinyl urea to stabilize white blood cells
SU1767436A1 (ru) 1990-05-22 1992-10-07 Черновицкий Государственный Университет Способ определени глюкозы в крови
US5260048A (en) 1991-05-08 1993-11-09 Streck Laboratories, Inc. Tissue fixative solution and method
US5270208A (en) * 1991-05-09 1993-12-14 Streck Laboratories, Inc. White blood cell hematology control
JPH0820452B2 (ja) 1991-12-16 1996-03-04 株式会社いかがく 血液中糖類の微生物による消費阻止方法
US5422277A (en) * 1992-03-27 1995-06-06 Ortho Diagnostic Systems Inc. Cell fixative composition and method of staining cells without destroying the cell surface
WO1993021928A1 (en) 1992-04-24 1993-11-11 Streck Laboratories, Inc. Liquid glucose control solution and process of making the same
US5407794A (en) * 1992-09-08 1995-04-18 Cytocolor Inc. Oxazine stained lymphocytes and method
EP0639985B1 (en) 1992-09-10 2004-08-11 Streck Laboratories, Inc. Method and composition for preserving antigens and process for utilizing cytological material produced by same
FR2705359B1 (fr) * 1993-05-19 1995-08-18 Immunotech Sa Méthode de protection des cellules leucocytaires, composition protectrice, composition de sang protégée, et méthode d'analyse sanguine.
US6197540B1 (en) 1993-07-05 2001-03-06 Northern General Hospital N.H.S. Trust Preparation and stabilization of cells using aged transition metal solutions
WO1995027203A1 (en) * 1994-04-05 1995-10-12 Northern General Hospital N.H.S. Trust Preparation and stabilisation of cell suspensions

Also Published As

Publication number Publication date
WO1995001796A1 (en) 1995-01-19
ATE241368T1 (de) 2003-06-15
GB2279653B (en) 1998-02-11
NO960049D0 (no) 1996-01-05
NZ271318A (en) 1998-08-26
AU4441096A (en) 1996-06-06
EP0708649A1 (en) 1996-05-01
JPH09503051A (ja) 1997-03-25
AU700699B2 (en) 1999-01-14
US6197540B1 (en) 2001-03-06
US6197539B1 (en) 2001-03-06
FI960045A (fi) 1996-01-05
GB9413558D0 (en) 1994-08-24
DE69432751D1 (de) 2003-07-03
CA2166729A1 (en) 1995-01-19
DE708649T1 (de) 2001-09-20
NO960049L (no) 1996-03-05
DE69432751T2 (de) 2004-04-29
GB2279653A (en) 1995-01-11
BR9407003A (pt) 1996-03-26
EP0708649B1 (en) 2003-05-28
AU7490994A (en) 1995-02-06
ES2197168T3 (es) 2004-01-01

Similar Documents

Publication Publication Date Title
FI960045A (fi) Solujen valmistus ja stabilointi
CO4820440A1 (es) Composiciones que contienen adenovirus recombinantes concentrados
ES2061791T3 (es) Composicion farmaceutica estabilizada y metodo para producirla.
DE69223641D1 (de) Stabilisierte antikörper
ES8506190A1 (es) Un metodo para estabilizar un activador de plasminogeno de tejido.
ATE25525T1 (de) N-glycosylierte carbonsaeureamid-derivate, verfahren zu ihrer herstellung sowie ihre verwendung zur beeinflussung der koerpereigenen abwehr.
ATE17363T1 (de) Verfahren zur herstellung von hochelastischen schaeumen und alkoxysilicium-verbindung(en) als schaumstabilisatoren hierfuer.
DE60116673D1 (de) Zellkonservierungsflüssigkeit und verfahren zur zellkonservierung mit dieser flüssigkeit
ATE287255T1 (de) Stabile flüssigkeiten mit hohem glycerolgehalt, die sulfosuccinsäuremonoester enthalten
ES8506621A1 (es) Procedimiento de preparar nuevas bencensulfonil-lactamas
ES2004240A6 (es) Una composicion de coenzima estabilizada
EP0568379A3 (en) Compositions and method for improving the wetting of particulates
DE3885577T2 (de) Luciferase.
JPS5576814A (en) Preservative solution for organ transplant
DE50001654D1 (de) Verfahren zur herstellung von polyvinylpyrrolidon-iod in wässriger lösung
SE7906137L (sv) Rening av faktor viii
ATE103974T1 (de) Verfahren zur stabilisierung des lactoperoxidase- enzyms in produkten.
JPS55164638A (en) Purification of phenol
JPS6452727A (en) Antiallergic eye drop
JPS5714587A (en) Stabilizing method of ascorbic acid
JPS531679A (en) Deodorizing method
KR840005318A (ko) 살균제 조성물
ATE18234T1 (de) Verfahren zur herstellung von 3-alpha,7-betadihydroxy-5-beta-cholansaeure.
JPS5421700A (en) Ion-beam processing method
YU4797A (sh) Žučne kiseline i njihovi derivati kao hipoglikemična sredstva